Company profile
Reviva Pharmaceuticals Holdings, Inc.
RVPH · NASDAQ (Late-stage US pharma company (lead asset brilaroxazine/RP5063 for schizophrenia); publicly traded on Nasdaq under RVPH. No existing roster row found for this name. Sources: https://clinicaltrials.gov/study/NCT01490086 ; https://data.sec.gov/submissions/CIK0001742927.json ; https://stockanalysis.com/stocks/rvph/ ; https://www.nasdaq.com/market-activity/stocks/rvph Entity resolved by asset-pipeline-v2.)
Share price · RVPH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Dopamine D2/D3/D4 and serotonin 5-HT1A/5-HT2A receptors (partial agonist); serotonin 5-HT2B/5-HT6/5-HT7 receptors (antagonist)Small molecule | Schizophrenia |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.